Pembrolizumab alone

DRUG2 trials

Sponsors

Prof. Dr. med. Dirk Schadendorf, National Cancer Centre, Singapore

Conditions

Colorectal CancerMalignant Melanoma

Phase 1

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

CompletedNCT02902042

Prof. Dr. med. Dirk SchadendorfMalignant Melanoma

Start: 2018-04-24End: 2020-11-30Updated: 2021-02-16

Phase 2

Window of Opportunity Study in Colorectal Cancer

CompletedNCT03984578

National Cancer Centre, SingaporeColorectal Cancer

Start: 2019-06-12End: 2025-02-28Updated: 2025-11-18

Related Papers

Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial.

2021-10-1317 citations

Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.

Journal of Clinical Oncology2021-05-204 citations